Clinical Update on Uses for Mifepristone in Obstetrics and Gynecology

∗Fellow, Division of Complex Family Planning, Department of Obstetrics and Gynecology, University of North Carolina–Chapel Hill, Chapel Hill, NC

†Fellow, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT

‡Associate Professor, Division of Complex Family Planning, Department of Obstetrics and Gynecology, University of North Carolina–Chapel Hill, Chapel Hill, NC

Jill M. Hagey and Amy G. Bryant have disclosed that the U.S. Food and Drug Administration has not approved the use of any drugs or devices for the treatment of early pregnancy loss, intrauterine fetal demise, ectopic pregnancy, pregnancy prevention, abnormal uterine bleeding, or gynecologic cancers as discussed in this article. Please consult the product’s labeling for approved information.

All authors, faculty, and staff have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Correspondence requests to: Jill M. Hagey, MD, MPH, 101 Manning Dr, Chapel Hill, NC 27514. E-mail: [email protected].

留言 (0)

沒有登入
gif